Impact of COVID-19 on HV trials [Study Per­for­mance]

posted by kratos – India, 2020-03-31 05:09 (1043 d 12:22 ago) – Posting: # 21308
Views: 1,655

Hi, certainly many many studies are impacted by the COVID situation.
Not the best time to initiate a new study; But does anyone have an experience where a trial had to be aborted half way ?
We completed Period 1 of a study in an Indian CRO and during the washout, the government issued a lock down, so period 2 is postponed until everything gets back to 'normalcy'.
My question here is, in case we have partial replicate study, and such a situation came up after completion of two periods, will it be acceptable to increase the washout for just the final period ? considering between period 1 and 2 we would have had a shorter washout, will this inconsistency be acceptable ?
Thanks

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
22 visitors (0 registered, 22 guests [including 11 identified bots]).
Forum time: 16:31 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5